To the full analysis
Tenet Healthcare stock: growth
THCTenet Healthcare reported $21.31B in revenue for fiscal 2025, up 3.1% on the prior year, up 3.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5%
per year from 2006 to 2025, per share 6.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 3.9% | 1.4% | 5.0% |
| Revenue per share | 7.1% | 2.3% | 6.5% |
| Earnings | 28.7% | no data | no data |
| Earnings per share | 32.7% | no data | no data |
| Free cash flow | −2.5% | 30.0% | no data |
| Free cash flow per share | 0.6% | 31.2% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $8.45B | −$803M | −$1.11B |
| 2007 | $8.08B | −$89M | −$403M |
| 2008 | $8.59B | $25M | −$339M |
| 2009 | $9.01B | $187M | −$31M |
| 2010 | $8.27B | $1.14B | −$4M |
| 2011 | $8.65B | $82M | $22M |
| 2012 | $9.12B | $152M | $85M |
| 2013 | $11.09B | −$134M | −$102M |
| 2014 | $16.6B | $12M | −$246M |
| 2015 | $18.63B | −$140M | $184M |
| 2016 | $19.62B | −$192M | −$317M |
| 2017 | $19.18B | −$704M | $493M |
| 2018 | $18.31B | $104M | $432M |
| 2019 | $18.48B | −$215M | $563M |
| 2020 | $17.64B | $399M | $2.87B |
| 2021 | $19.49B | $914M | $910M |
| 2022 | $19.17B | $411M | $321M |
| 2023 | $20.55B | $611M | $1.62B |
| 2024 | $20.67B | $3.2B | $1.12B |
| 2025 | $21.31B | $1.41B | $2.53B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 24 Jul 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.